Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 6, 2022

MARLBOROUGH, Mass., Oct. 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it is scheduled to provide an update on its programs at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Boston, MA from November 8 - 12, 2022. This will include an update on its first-in-human clinical trial with PH-762 in advanced melanoma; data demonstrating the potential of PH-762 to further enhance the function of tumor infiltrating lymphocytes (TILs) with its partner AgonOx, Inc.; and new preclinical data on relevant targets identified in cancer immunotherapy using our INTASYL compounds.

Presentation Details are as follows:

1. **Title:** Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYL™ PH-762 (in collaboration with AgonOx, Inc.)
   - **Abstract #:** 409
   - **Presenting Author:** Colin Thalhofer (AgonOx, Inc.)
   - **Date and Time:** 9:00 am - 9:00 pm on Thursday, November 10th
   - **Location:** Hall C

2. **Title:** Local immunotherapy with INTASYL™ self-delivering RNAi targeting CTLA-4 provides robust tumor control in vivo
   - **Abstract #:** 537
   - **Presenting Author:** Ben Cuiffo
   - **Date and Time:** 9:00 am - 9:00 pm on Thursday, November 10th
   - **Location:** Hall C

3. **Title:** Intratumoral PH-109 INTASYL™ self-delivering RNAi targeting connective tissue growth factor (CTGF) provides efficacy in a mouse model of metastatic breast cancer
   - **Abstract #:** 1431
   - **Presenting Author:** Ben Cuiffo
   - **Date and Time:** 9:00 am - 9:00 pm on Thursday, November 10th
   - **Location:** Hall C

4. **Title:** PH-804, an INTASYL™ self-delivering RNAi compound that targets TIGIT enhances NK cell cytotoxicity to tumor cells
   - **Abstract #:** 493
   - **Presenting Author:** Melissa Maxwell
   - **Date and Time:** 9:00 am - 9:00 pm on Thursday, November 10th
   - **Location:** Hall C

5. **Title:** A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of neoadjuvant use of PH-762 administered intratumorally in subjects with advanced melanoma (in collaboration with Gustave Roussy, Caroline Robert primary author)
   - **Abstract #:** 788
   - **Presenting Author:** Simon Fricker
   - **Date and Time:** 9:00 am - 8:30 pm on Friday, November 11th
   - **Location:** Hall C

6. **Title:** PH-894, an INTASYL™ self-delivering siRNA targeting BRD4, has dual functions to sensitize tumor cell killing and activate CD8 T cells
   - **Abstract #:** 1402
   - **Presenting Author:** Shenghua Zhou
   - **Date and Time:** 9:00 am - 8:30 pm on Friday, November 11th
   - **Location:** Hall C

The poster presentations will be accessible in person and will also be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. Our goal is...
to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, military conflict between Ukraine and Russia, inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC.

Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com

Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com


SOURCE Phio Pharmaceuticals Corp.